125903-81-3

Basic information

• Product Name: 3-(DIFLUOROMETHOXY)BENZYL ALCOHOL
• Synonyms: 3-(DIFLUOROMETHOXY)BENZYL ALCOHOL;RARECHEM AL BD 0447;alpha,alpha-Difluoro-3-(hydroxymethyl)anisole, [3-(Difluoromethoxy)phenyl]methanol;(3-(Difluoromethoxy)phenyl)methanol
• CAS NO: 125903-81-3
• Molecular Formula: C₈H₈F₂O₂
• Molecular Weight: 174.14
• Mol File: 125903-81-3.mol

Chemical Properties

• Boiling Point: 242.2 °C at 760 mmHg
• Flash Point: 118.9 °C
• Appearance: /
• Density: 1.257 g/cm³
• Vapor Pressure: 0.0185mmHg at 25°C
• Refractive Index: 1.484
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 3-(DIFLUOROMETHOXY)BENZYL ALCOHOL(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(DIFLUOROMETHOXY)BENZYL ALCOHOL(125903-81-3)
• EPA Substance Registry System: 3-(DIFLUOROMETHOXY)BENZYL ALCOHOL(125903-81-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• Hazardous Substances Data: 125903-81-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-(Difluoromethoxy)benzyl alcohol is utilized as a reagent in organic synthesis for its ability to participate in various chemical reactions, contributing to the formation of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3-(Difluoromethoxy)benzyl alcohol is employed as a pharmaceutical intermediate. Its role is crucial in the synthesis of active pharmaceutical ingredients, where its unique structure and properties can be leveraged to create new and effective medications.
Used in Chemical Reactions and Processes:
Due to its stability and reactivity, 3-(Difluoromethoxy)benzyl alcohol is used in a range of chemical reactions and processes, where it can act as a key component in the production of various chemical products.

InChI:InChI=1/C8H8F2O2/c9-8(10)12-7-3-1-2-6(4-7)5-11/h1-4,8,11H,5H2

Upstream product

• 75-45-6 Chlorodifluoromethane 
• 620-24-6 3-Hydroxybenzyl alcohol 
• 100-83-4 meta-hydroxybenzaldehyde 
• 85684-61-3 3-(difluoromethoxy)-benzaldehyde 

Downstream Products

• 85684-61-3 3-(difluoromethoxy)-benzaldehyde 
• 438047-64-4 3-Difluoromethoxybenzyl cis-2,6-dimethylpiperazine-1-carboxylate fumarate 
• 97603-96-8 3-Difluoromethoxy-benzamidine; hydrochloride 
• 97603-92-4 3-Difluoromethoxy-benzaldehyde oxime 
• 97582-88-2 3-(Difluoromethoxy)benzonitrile 

Relevant articles and documents

IMIDAZOLIDINONE DERIVATIVES AS INHIBITORS OF PERK

The invention is directed to substituted imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I (I) wherein R1, R2, R3, R4, R5, R6, R7, X, Y1, Y2 and Z are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes, as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob Disease, fatal familial insomnia, Gerstmann-Str?ussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Preparation of Triazolopyrimidines as Potential Antiasthma Agents

With the use of the human basophil histamine release assay, 5-aryl-2-aminotriazolopyrimidines were found to be active as mediator release inhibitors.These compounds were prepared by reacting arylamidines with sodium ethyl formylacetate or with ethyl propiolate to give pyrimidinones.Treatment with phosphorus oxychloride gave a chloropyrimidine, which was converted to a hydrazinopyrimidine with hydrazine.Cyclization, using cyanogen bromide, gave the triazolopyrimidines, after a Dimroth rearrangement.Following a structure-activity evaluation, the5--2-amino (8-10), 5-(3-bromophenyl)-2-amino (8-13), 5--2-amino (8-11), and 5-(4-pyridinyl)-2-amino (6-7) compounds were found to have the best activity.They were chosen for further pharmacological and toxicological study.